Arvinas Inc
ARVN
Company Profile
Business description
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Contact
395 Winchester Avenue
5 Science Park
New HavenCT06511
USAT: +1 203 535-1456
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
445
Stocks News & Analysis
stocks
What Nvidia’s earnings say about the AI semiconductor stock trade
Six charts on Nvidia stock and the outlook for AI-focused semiconductors.
stocks
Hard times continue for former ASX highflyer
We lower our fair value and believe the company is in an uncompetitive position but shares screen as undervalued due to investor pessimism.
stocks
2 companies I'd love to own shares in one day
A look at two companies that embody some qualities I love to see in a potential investment. If only the price was right.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,661.20 | 28.10 | 0.33% |
| CAC 40 | 7,257.47 | 2.46 | 0.03% |
| DAX 40 | 19,405.20 | 82.61 | 0.43% |
| Dow JONES (US) | 44,565.79 | 269.28 | 0.61% |
| FTSE 100 | 8,291.68 | 29.60 | 0.36% |
| HKSE | 19,150.99 | 78.98 | -0.41% |
| NASDAQ | 19,015.79 | 12.14 | 0.06% |
| Nikkei 225 | 38,780.14 | 496.29 | 1.30% |
| NZX 50 Index | 13,196.08 | 154.18 | 1.18% |
| S&P 500 | 5,975.81 | 6.47 | 0.11% |
| S&P/ASX 200 | 8,417.60 | 23.80 | 0.28% |
| SSE Composite Index | 3,263.76 | 3.43 | -0.11% |